Femasys Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving its listing concerns. This milestone allows the company to focus on expanding access to its innovative fertility and non-surgical permanent birth control products globally. Femasys is actively commercializing products like FemaSeed, FemBloc, and FemVue, with ongoing clinical trials and regulatory approvals in multiple countries. The company aims to build long-term value through strategic partnerships and continued product development.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
7-Eleven and Mattel's Hot Wheels have teamed up to release an exclusive 2017 Nissan GT-R (R35) die-cast supercar. Available at select 7-Eleven, Speedway, and Stripes stores as well as online at 7Collection.com, this collectible features a white wrap ...
Guardian Exploration has finished a high-resolution airborne magnetic and radiometric survey over its Mount Cameron Project in Yukon, Canada, aimed at identifying geological features that control silver-lead-zinc mineralization. The survey data will ...
Analyst The Curious Analyst rates Teradyne as a buy with a $484 price target, suggesting a 43% upside from its current $339 price. The company’s earnings are expected to grow due to AI advancements, increased chip complexity, and expanded testing nee...
